MT1 (Melanotan-1): Structure, MC1R Mechanism, and Research Applications

Melanotan-1 (MT1) is a synthetic 13-amino-acid peptide structurally related to endogenous alpha-melanocyte-stimulating hormone (α-MSH), carrying two substitutions (Nle⁴, D-Phe⁷) that alter receptor interaction and metabolic stability. Notably, this exact structure — Nle⁴-D-Phe⁷-α-MSH — is also the active compound in Scenesse (afamelanotide), an FDA-approved drug for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP). As interest in products marketed under terms such as "Melanotan-1 for sale" continues to grow online, it is important to distinguish investigational compounds and commercial claims from approved medical applications. This article covers MT1's melanocortin receptor mechanism and research findings, and corrects a citation error found in the source material's porphyria-related trial data.

Table of Contents

1. Key Facts at a Glance
2. Regulatory Identity: MT1 and Scenesse (Afamelanotide)
3. Mechanism of Action: MC1R Signaling
4. MT1 Within the Melanocortin Receptor Network
5. MC1R Signaling in Melanocyte Photoprotection
6. Photosensitivity Research in Erythropoietic Porphyria
7. Research Under UV Radiation Exposure (Human Volunteers)
8. MC1R Signaling Beyond Pigmentation
9. Emerging Neuromelanin/Parkinson's Research (Exploratory)
10. Evidence Summary by Study
11. Storage and Stability
12. Frequently Asked Questions
13. Key Takeaways
14. References

Key Facts at a Glance

Regulatory Identity: MT1 and Scenesse (Afamelanotide)

MT1's structure — Nle⁴-D-Phe⁷-α-MSH — is identical to afamelanotide, the active compound in the FDA-approved drug Scenesse.

Scenesse is approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. This is directly relevant to the porphyria-related research covered later in this article: [1] in the source material is itself a PubChem entry for Scenesse, though the connection was not stated explicitly in the original source content. Research-grade MT1 sold for laboratory use is a distinct, non-pharmaceutical-grade product from the regulated drug.

Mechanism of Action: MC1R Signaling

MT1 is hypothesized to act primarily through MC1R, a Gs-coupled receptor expressed predominantly on melanocytes, triggering a cAMP-driven signaling cascade that promotes eumelanin synthesis.

MC1R activation is thought to stimulate adenylyl cyclase, raising intracellular cAMP and influencing microphthalmia-associated transcription factor (MITF) expression, which drives transcription of enzymes involved in eumelanin production [3]. MT1 has also been used as an agonist probe across other melanocortin receptor subtypes in vitro and in animal models, characterizing receptor-specific signaling outputs and second-messenger activation under standardized conditions.

MT1 Within the Melanocortin Receptor Network

MT1 shows apparent preferential interaction with MC1R, with comparative studies indicating higher relative MC1R affinity than endogenous α-MSH under experimental conditions, supporting elevated MITF-driven eumelanin synthesis [2][4].

MC1R Signaling in Melanocyte Photoprotection

Research suggests MC1R activation may support nucleotide excision repair — the pathway that removes UV-associated DNA lesions — in addition to its role in pigmentation, though this appears to depend on receptor polymorphism status.

MC1R activation is hypothesized to modulate melanogenic processes and melanin distribution in ways that may contribute to photoprotection and cellular resilience against UV damage. Elevated cAMP signaling has been proposed to support DNA repair capacity, potentially reducing mutational burden in melanocytes [3]. However, loss-of-function MC1R polymorphisms have been associated with reduced pigmentation, increased UV sensitivity, and diminished DNA repair efficiency — meaning genetic background may shape how strongly an agonist like MT1 can influence these pathways in a given individual or experimental model. MC1R signaling has also been implicated in broader anti-inflammatory activity and melanocyte genomic stability maintenance.

Photosensitivity Research in Erythropoietic Porphyria

Important citation note: the source material cites reference [5] for this section, but reference [5] is actually Lee et al. (2006), a study of α-MSH gene therapy for liver fibrosis in mice — unrelated to erythropoietic porphyria or human trials. The specific trial data below (three controlled trials, 64 vs. 40 hours sun tolerance, 180-day observation) has no valid supporting citation in the material provided and should not be published without locating the correct source.

The uncited description states that three controlled clinical investigations examined MT1/afamelanotide in models of erythropoietic porphyria, with participants stratified into peptide-exposed and placebo cohorts, exposure repeated at two-month intervals over up to 180 days, tracking sunlight exposure duration and pain response during UV exposure. Peptide-exposed groups reportedly tolerated longer cumulative sunlight exposure (~64 hours) with reduced pain versus placebo (~40 hours). Given this compound's identity as the active ingredient in Scenesse (a drug specifically approved for this indication), these findings are directionally consistent with published afamelanotide EPP trial literature — but the correct primary source needs to be identified and cited before this content is published.

Research Under UV Radiation Exposure (Human Volunteers)

This is genuine, correctly cited human clinical research — Dorr et al. (2004), published under the title "...tanning of the skin in human volunteers."

Three independent Phase I trials evaluated MT1 exposure relative to UVB radiation or daylight. The first study assigned equal proportions of participants to peptide and placebo conditions over ten days; a second examined UV exposure parameters across similarly distributed cohorts; a third used an equal peptide/placebo allocation. Post-exposure analyses focused on cellular responses and observable pigmentation changes, with results suggesting an association between peptide exposure, UV interaction, and increased melanin-related activity — interpreted by the original researchers as indicative of a possible correlation rather than definitive causation [6].

MC1R Signaling Beyond Pigmentation

A pharmacological review described MC1R as having "pleiotropic signaling capacity," with activation associated with inflammatory modulation and cellular stress adaptation pathways beyond melanogenesis, potentially promoting anti-inflammatory signaling independently of melanin synthesis in some experimental systems. The review discussed peptide-based melanocortin agonists as molecular probes for revealing signaling bias and pathway selectivity beyond pigmentation endpoints [7].

Emerging Neuromelanin/Parkinson's Research (Exploratory)

This is a conceptual/theoretical review published in a newly established journal (December 2025), not primary experimental data on MT1 specifically. Treat as early-stage and exploratory.

A late-2025 conceptual review explored theoretical connections between melanocortin receptor agonism and neuromelanin-associated pathways in experimental neurodegenerative models, drawing parallels between eumelanin synthesis in melanocytes and neuromelanin accumulation in specific neuronal populations. The review did not focus specifically on MT1 and presented its hypotheses as exploratory and largely inferential, based on mechanistic overlap rather than direct experimental validation [8].

Evidence Summary by Study

Storage and Stability

Key Takeaways

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 16154396, Scenesse. https://pubchem.ncbi.nlm.nih.gov/compound/Scenesse
2. Cai M, Hruby VJ. The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases. Curr Protein Pept Sci. 2016;17(5):488-496. https://doi.org/10.2174/1389203717666160226145330
3. Wolf Horrell EM, Boulanger MC, D'Orazio JA. Melanocortin 1 Receptor: Structure, Function, and Regulation. Front Genet. 2016;7:95. https://pubmed.ncbi.nlm.nih.gov/27303435/
4. Mun Y, Kim W, Shin D. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. Int J Mol Sci. 2023;24(15):12152. https://pubmed.ncbi.nlm.nih.gov/37569558/
5. Lee TH, Jawan B, Chou WY, et al. Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis in mice. J Gene Med. 2006;8(6):764-72. https://pubmed.ncbi.nlm.nih.gov/16508911/ (Note: this reference does not support the porphyria trial claims it was cited for in the source material — see correction above.)
6. Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004. https://pubmed.ncbi.nlm.nih.gov/15262693/
7. Mun Y, Kim W, Shin D. Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. Int J Mol Sci. 2023;24(15):12152. https://pubmed.ncbi.nlm.nih.gov/37569558/
8. Pendergrass K, Eyer K. Melanotan Peptides as Potential Therapeutics in Parkinson's Disease. Microbiome Medicine (Translational Microbiome Medicine Research). December 2025. (Recently established journal; treat as exploratory/theoretical literature.)